The gel has been used to treat various types of joints. In clinical practice, it has been used on knee, hip, shoulder, and ankle joints, as well as smaller joints. According to available data, it has been used in over 20,000 patients worldwide.
The treatment is CE certified, and clinical experience indicates that many patients reported reduced joint pain and improved joint mobility and function after the treatment.
However, this method is not suitable for all cases. The gel is primarily intended for the treatment of small, well-defined cartilage lesions. In cases of extensive joint wear or advanced arthritis, other treatment options may be necessary.
Although the procedure is minimally invasive, it is still considered surgical and therefore carries standard medical risks.
ChondroFiller® may offer some patients a simpler treatment option compared to traditional joint replacements or cellular implants. This technology is a branch of regenerative medicine, where research is aimed at developing bioactive, fully degradable gels that more effectively support cartilage tissue repair.
